论文部分内容阅读
目的:探讨五味心安胶囊联合低分子肝素治疗不稳定型心绞痛(UAP)的疗效。方法:60例UAP患者随机分为两组,治疗组30例,对照组30例。两组均给予常规治疗及皮下注射低分子肝素治疗,治疗组加服五味心安胶囊。两组连续观察7天。结果:治疗组有效率96.7%,对照组有效率80%。治疗组凝血酶原时间(PT)及纤维蛋白原定量(FIB)与对照组比较差异有统计学意义(P<0.05),用药后部分出凝血指标与对照组比较有明显变化,但均在正常范围内。结论:五味心安胶囊联合低分子肝素治疗不稳定型心绞痛临床疗效明显、安全。
Objective: To investigate the curative effect of Wuwei Xin’an Capsule combined with low molecular weight heparin in the treatment of unstable angina pectoris (UAP). Methods: Sixty UAP patients were randomly divided into two groups: 30 cases in the treatment group and 30 cases in the control group. Both groups were given routine treatment and subcutaneous injection of low molecular weight heparin treatment, the treatment group plus serving Wuwei Xinan capsule. The two groups were observed for 7 days. Results: The effective rate was 96.7% in the treatment group and 80% in the control group. The treatment group prothrombin time (PT) and fibrinogen quantitative (FIB) compared with the control group, the difference was statistically significant (P <0.05), some of the coagulation index after treatment compared with the control group were significantly changed, but were normal Range. Conclusion: Weweixinan capsule combined with low molecular weight heparin in the treatment of unstable angina pectoris has obvious curative effect and safety.